Skip to content
Inciteful Med

Understanding Your Risk and Long-Term Monitoring

Last updated:

Long-term monitoring for Primary Biliary Cholangitis (PBC) uses non-invasive tools like FibroScan and blood-based GLOBE scores to track liver health and predict future risks. Regular screening is also essential to manage associated conditions like osteoporosis and thyroid disease.

Key Takeaways

  • • GLOBE and UK-PBC scores use routine blood work to accurately estimate your long-term risk of liver complications without the need for a biopsy.
  • • FibroScan is a non-invasive ultrasound that measures liver stiffness, helping doctors safely track disease progression over time.
  • • Because up to 45% of patients with PBC develop osteoporosis, baseline and regular bone density (DEXA) scans are an essential part of care.
  • • PBC increases the risk of other autoimmune conditions, particularly thyroid and celiac disease, which require ongoing screening.
  • • A standard monitoring schedule includes blood work every 3 to 6 months and a FibroScan every 1 to 2 years to track liver health.

Managing Primary Biliary Cholangitis (PBC) requires a long-term perspective. While the diagnosis can be overwhelming, modern tools allow your medical team to accurately predict your risk and monitor your liver health without always needing invasive procedures like biopsies.

Predicting Your Future Risk

To understand how well you are responding to treatment, doctors use specialized calculators. The two most common are the GLOBE score and the UK-PBC score [1][2].

  • How They Work: These tools use your lab results—typically after you have been on treatment (UDCA) for 12 months—to estimate your long-term risk of needing a liver transplant [3][4].
  • Key Lab Markers: These scores look at several “ingredients” from your blood work, including Alkaline Phosphatase (ALP), bilirubin, albumin, platelets, and your age [3][5].
  • The Goal: A stable or improving score is a strong sign that your current treatment is protecting your liver [6][7].

Non-Invasive Monitoring

Monitoring liver health no longer requires frequent biopsies. Instead, doctors use “non-invasive” tools to measure liver stiffness and scarring (fibrosis) [8][9].

  • FibroScan (VCTE): This is a specialized ultrasound that measures how fast a vibration travels through your liver. The faster it moves, the “stiffer” (more scarred) the liver is [8][9].
    • Low Risk: A score below 8 kPa generally indicates a lower risk of complications [10][11].
    • Higher Risk: A score above 15 kPa suggests a higher risk and the need for closer monitoring [10][11].
  • ELF Score: The Enhanced Liver Fibrosis (ELF) score is a blood test that looks for markers of scarring. A score of 10.0 or higher often signals a need for more intensive management [12].

Long-Term Risks and Survivorship

Because PBC is an autoimmune condition, it can affect other parts of your body. Monitoring these “extrahepatic” (outside the liver) risks is a vital part of your care.

  1. Bone Health (Osteoporosis): Up to 45% of people with PBC develop osteoporosis (weakened bones) [13][14]. Because PBC impairs bile flow, it can block the absorption of fat-soluble vitamins (like Vitamin D) [15]. Guidelines recommend a DEXA scan (bone density test) at the time of diagnosis [16][17].
  2. Thyroid and Celiac Disease: Thyroid issues (affecting up to 25% of patients) and celiac disease are significantly more common in those with PBC [18][19][20]. Regular blood tests (like TSH) are often used to screen for these conditions [19].
  3. Liver Complications: While the overall risk is low, people with advanced liver scarring (cirrhosis) have a higher risk of hepatocellular carcinoma (HCC) (liver cancer) [21][22]. Additionally, for patients who have progressed to cirrhosis, an endoscopy is recommended to screen for enlarged veins in the esophagus (esophageal varices) [23].

Recommended Monitoring Schedule

While every patient is different, a typical surveillance schedule includes:

  • Blood Work (ALP, Bilirubin): Every 3–6 months [24].
  • FibroScan: Once every 1–2 years to track scarring [25].
  • Liver Ultrasound: Every 6 months if you have cirrhosis (to screen for cancer) [26][23].
  • Endoscopy: Only for patients with advanced cirrhosis, to screen for varices [23].
  • DEXA Scan: Every 2–3 years, depending on your initial results and risk factors [17].
  • Thyroid Testing: Annually or if symptoms of fatigue worsen [19].

Frequently Asked Questions

What do the GLOBE and UK-PBC scores mean?
The GLOBE and UK-PBC scores are calculators that use your routine lab results to estimate your long-term risk of needing a liver transplant. A stable or improving score after 12 months of treatment is a strong sign that your current therapy is protecting your liver.
What is a FibroScan and what does the score mean for PBC?
A FibroScan is a specialized, non-invasive ultrasound that measures liver stiffness to check for scarring. A score below 8 kPa suggests a lower risk of complications, while a score above 15 kPa indicates higher risk and the need for closer monitoring.
Why do I need a bone density (DEXA) scan if I have PBC?
Up to 45% of people with PBC develop osteoporosis, or weakened bones. This happens because impaired bile flow can block the absorption of fat-soluble vitamins like Vitamin D. A DEXA scan checks your bone density so your doctor can recommend supplements or treatments if needed.
How often should I get blood work done for PBC?
A standard monitoring schedule for PBC includes blood work to check liver markers like ALP and bilirubin every 3 to 6 months. Your care team may adjust this timeline based on your specific disease stage and how well you are responding to treatment.
Does PBC increase my risk for other autoimmune diseases?
Yes, people with PBC have a higher risk of developing other autoimmune conditions, particularly thyroid disease and celiac disease. Your doctor will typically recommend an annual thyroid test and symptom checks to screen for these related issues.

Questions for Your Doctor

  • • What are my current GLOBE and UK-PBC scores, and what do they tell us about my risk over the next 10 years?
  • • Based on my FibroScan (VCTE) results, what is my current stage of liver stiffness, and how has it changed since my last scan?
  • • Since I have PBC, how often should we be checking my thyroid (TSH) and screening for celiac disease?
  • • Given my bone density results, do I need to start a bisphosphonate, or are calcium and vitamin D supplements enough for now?
  • • If my liver stiffness reaches a certain threshold (like 15 kPa), how will my monitoring or treatment plan change?

Questions for You

  • • Have I had a DEXA scan since my diagnosis to check my bone health?
  • • Am I experiencing any new symptoms that might suggest another autoimmune issue, such as unexplained weight changes (thyroid) or digestive upset (celiac)?
  • • Do I have a consistent schedule for my blood work (typically every 3–6 months) and imaging?
  • • Am I taking my calcium and vitamin D supplements as recommended by my care team?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Risk stratification and prognostic modelling in primary biliary cholangitis.

    Goet JC, Harms MH, Carbone M, Hansen BE

    Best practice & research. Clinical gastroenterology 2018; (34-35()):95-106 doi:10.1016/j.bpg.2018.06.006.

    PMID: 30343715
  2. 2

    Prognostic modeling in biliary diseases.

    Ciobanu C, Russo MW

    Current opinion in gastroenterology 2023; (39(2)):89-94 doi:10.1097/MOG.0000000000000911.

    PMID: 36821456
  3. 3

    Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.

    van Buuren HR, Lammers WJ, Harms MH, Hansen BE

    Digestive diseases (Basel, Switzerland) 2015; (33 Suppl 2()):118-24 doi:10.1159/000440759.

    PMID: 26642225
  4. 4

    GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate.

    Li SX, Li BE, Li M, et al.

    Journal of digestive diseases 2025; (26(5-6)):250-259 doi:10.1111/1751-2980.13359.

    PMID: 40748579
  5. 5

    The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.

    Carbone M, Sharp SJ, Flack S, et al.

    Hepatology (Baltimore, Md.) 2016; (63(3)):930-50 doi:10.1002/hep.28017.

    PMID: 26223498
  6. 6

    Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.

    de Veer RC, van Hooff MC, Corpechot C, et al.

    The American journal of gastroenterology 2023; (118(7)):1196-1203 doi:10.14309/ajg.0000000000002128.

    PMID: 36621963
  7. 7

    Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.

    Roberts SB, Choi WJ, Worobetz L, et al.

    JHEP reports : innovation in hepatology 2024; (6(10)):101168 doi:10.1016/j.jhepr.2024.101168.

    PMID: 39380718
  8. 8

    Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study.

    Alvaro D, Calvaruso V, Carbone M, et al.

    Liver international : official journal of the International Association for the Study of the Liver 2025; (45(6)):e70118 doi:10.1111/liv.70118.

    PMID: 40318123
  9. 9

    Diagnostic accuracy of vibration-controlled transient elastography for staging liver fibrosis in autoimmune liver diseases: A systematic review and meta-analysis.

    An J, Chon YE, Kim G, et al.

    Clinical and molecular hepatology 2024; (30(Suppl)):S134-S146 doi:10.3350/cmh.2024.0586.

    PMID: 39165158
  10. 10

    Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.

    Corpechot C, Carrat F, Gaouar F, et al.

    Journal of hepatology 2022; (77(6)):1545-1553 doi:10.1016/j.jhep.2022.06.017.

    PMID: 35777587
  11. 11

    Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

    Wong YJ, Lam L, Soret PA, et al.

    Journal of hepatology 2026; (84(2)):275-283 doi:10.1016/j.jhep.2025.09.024.

    PMID: 41047080
  12. 12

    Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis.

    Fujinaga Y, Namisaki T, Takaya H, et al.

    Medicine 2021; (100(39)):e27403 doi:10.1097/MD.0000000000027403.

    PMID: 34596167
  13. 13

    [THE ROLE OF NUTRITION IN THE GENESIS OF-HEPATIC OSTEODYSTROPHY IN PRIMARY BILIARY CIRRHOSIS].

    Prashnova MK, Raikhelson KL, Ivanova OE, et al.

    Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 2015; 30-3.

    PMID: 27017740
  14. 14

    Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis.

    Chen JL, Liu Y, Bi YF, Wang XB

    World journal of gastroenterology 2023; (29(29)):4580-4592 doi:10.3748/wjg.v29.i29.4580.

    PMID: 37621753
  15. 15

    [Bone disease in primary biliary cirrhosis].

    Shibata H, Nakao K

    Clinical calcium 2015; (25(11)):1633-8.

    PMID: 26503867
  16. 16

    [Clinical guidelines for bone disease in primary biliary cirrhosis].

    Ishibashi H, Komori A

    Clinical calcium 2015; (25(11)):1675-80.

    PMID: 26503873
  17. 17

    Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges.

    Trivedi HD, Danford CJ, Goyes D, Bonder A

    Clinical and experimental gastroenterology 2020; (13()):17-24 doi:10.2147/CEG.S204638.

    PMID: 32021374
  18. 18

    Dissecting causal relationships between primary biliary cholangitis and extrahepatic autoimmune diseases based on Mendelian randomization.

    Ma G, Yang J, Wang X, et al.

    Scientific reports 2024; (14(1)):11528 doi:10.1038/s41598-024-62509-x.

    PMID: 38773317
  19. 19

    The Causal Effects of Primary Biliary Cholangitis on Thyroid Dysfunction: A Two-Sample Mendelian Randomization Study.

    Huang P, Hou Y, Zou Y, et al.

    Frontiers in genetics 2021; (12()):791778 doi:10.3389/fgene.2021.791778.

    PMID: 34956333
  20. 20

    Prevalence of Celiac Disease in Patients with Primary Biliary Cholangitis.

    Callichurn K, Cvetkovic L, Therrien A, et al.

    Journal of the Canadian Association of Gastroenterology 2021; (4(1)):44-47 doi:10.1093/jcag/gwz039.

    PMID: 33644676
  21. 21

    Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

    Natarajan Y, Tansel A, Patel P, et al.

    Digestive diseases and sciences 2021; (66(7)):2439-2451 doi:10.1007/s10620-020-06498-7.

    PMID: 32743773
  22. 22

    Current Perspectives on the Molecular and Clinical Relationships between Primary Biliary Cholangitis and Hepatocellular Carcinoma.

    Floreani A, Gabbia D, De Martin S

    International journal of molecular sciences 2024; (25(4)) doi:10.3390/ijms25042194.

    PMID: 38396870
  23. 23

    A Health Economic Evaluation of Routine Hepatocellular Carcinoma Surveillance for People with Compensated Cirrhosis to Support Australian Clinical Guidelines.

    Worthington J, He E, Caruana M, et al.

    MDM policy & practice 2025; (10(1)):23814683251344962 doi:10.1177/23814683251344962.

    PMID: 40584144
  24. 24

    Widespread gaps in the quality of care for primary biliary cholangitis in UK.

    Sivakumar M, Gandhi A, Shakweh E, et al.

    Frontline gastroenterology 2022; (13(1)):32-38 doi:10.1136/flgastro-2020-101713.

    PMID: 34966531
  25. 25

    Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis.

    Lam L, Soret PA, Lemoinne S, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2024; (22(12)):2432-2441.e2 doi:10.1016/j.cgh.2024.06.035.

    PMID: 39019421
  26. 26

    Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations.

    George J, Allard NL, Roberts SK, et al.

    The Medical journal of Australia 2025; (223(8)):426-436 doi:10.5694/mja2.70061.

    PMID: 40976940

This page provides educational information about Primary Biliary Cholangitis (PBC) monitoring and risk prediction. Always consult your hepatologist or care team to interpret your specific lab results and imaging.

Stay up to date

Get notified when new research about Primary biliary cholangitis is published.

No spam. Unsubscribe anytime.